Impact Of Concomitant Prostate Cancer Therapy On Efficacy And Safety Of Relugolix Versus Leuprolide In Men With Advanced Prostate Cancer: Subgroup Analysis From The Phase Iii Hero Study.

Daniel J. George,Neal D. Shore,Fred Saad,Michael Cookson,Daniel Saltzstein,Ronald F. Tutrone,Hideyuki Akaza,Alberto Bossi,Elaine K. Wong,Bryan Selby,Xiaolin Fan,Jackie Walling,Bertrand Tombal

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 5|浏览14

暂无评分

摘要

106Background: In the phase 3 HERO study, the oral GnRH receptor antagonist, relugolix, demonstrated suppression of testosterone to castrate levels in 96.7% of patients, which was superior to leupr...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要